Poms AD - Search Results

1

Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis.

Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Poms AD, et al. Chest. 2013 Jul;144(1):169-176. doi: 10.1378/chest.11-3241. Chest. 2013. PMID: 23348820

2

Five-Year outcomes of patients enrolled in the REVEAL Registry.

Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL. Farber HW, et al. Among authors: poms ad. Chest. 2015 Oct;148(4):1043-54. doi: 10.1378/chest.15-0300. Chest. 2015. PMID: 26066077 Free article. Clinical Trial.

3

United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics.

Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC, Elliott CG; USPHSR Investigators. Badlam JB, et al. Among authors: poms ad. Chest. 2021 Jan;159(1):311-327. doi: 10.1016/j.chest.2020.07.088. Epub 2020 Aug 26. Chest. 2021. PMID: 32858008 Free PMC article.

4

Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®.

Kitterman N, Poms A, Miller DP, Lombardi S, Farber HW, Barst RJ. Kitterman N, et al. Mayo Clin Proc. 2012 Sep;87(9):825-34. doi: 10.1016/j.mayocp.2012.05.014. Epub 2012 Aug 9. Mayo Clin Proc. 2012. PMID: 22883740 Free PMC article.

5

United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications.

Elliott CG, Austin ED, Badesch D, Badlam J, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC. Elliott CG, et al. Among authors: poms ad. Pulm Circ. 2019 Apr-Jun;9(2):2045894019851696. doi: 10.1177/2045894019851696. Pulm Circ. 2019. PMID: 31099303 Free PMC article.

6

Inhaled treprostinil for the treatment of pulmonary arterial hypertension.

Poms A, Kingman M. Poms A, et al. Crit Care Nurse. 2011 Dec;31(6):e1-10. doi: 10.4037/ccn2011153. Crit Care Nurse. 2011. PMID: 22135338 Review.

7

Treatment-related biomarkers in pulmonary hypertension patients on oral therapies.

Swaminathan AC, Zhu H, Tapson V, Lokhnygina Y, Poms A, Kelleher Z, Gaspard E, Kennedy K, Fee BE, Fortin T, Mason SN, Parikh K, McMahon TJ. Swaminathan AC, et al. Respir Res. 2020 Nov 19;21(1):304. doi: 10.1186/s12931-020-01566-y. Respir Res. 2020. PMID: 33213478 Free PMC article.

8

Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension.

Parikh KS, Rajagopal S, Fortin T, Tapson VF, Poms AD. Parikh KS, et al. Among authors: poms ad. J Cardiovasc Pharmacol. 2016 Apr;67(4):322-5. doi: 10.1097/FJC.0000000000000357. J Cardiovasc Pharmacol. 2016. PMID: 26828324 Free PMC article.

9

Comprehensive assessment of right ventricular function in patients with pulmonary hypertension with global longitudinal peak systolic strain derived from multiple right ventricular views.

Rajagopal S, Forsha DE, Risum N, Hornik CP, Poms AD, Fortin TA, Tapson VF, Velazquez EJ, Kisslo J, Samad Z. Rajagopal S, et al. Among authors: poms ad. J Am Soc Echocardiogr. 2014 Jun;27(6):657-665.e3. doi: 10.1016/j.echo.2014.02.001. Epub 2014 Mar 20. J Am Soc Echocardiogr. 2014. PMID: 24656881

10

One-year experience with intravenous treprostinil for pulmonary arterial hypertension.

Benza RL, Tapson VF, Gomberg-Maitland M, Poms A, Barst RJ, McLaughlin VV. Benza RL, et al. J Heart Lung Transplant. 2013 Sep;32(9):889-96. doi: 10.1016/j.healun.2013.06.008. J Heart Lung Transplant. 2013. PMID: 23953817 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters